Clinical Trials Directory

Trials / Completed

CompletedNCT07382843

Melatonin Agonist for Shift-time Workers.

The Study of the Relationship Between Sleep Pattern, Attention Performance, and Heart Rate Variability Among Night Workers.

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
61 (actual)
Sponsor
Tri-Service General Hospital · Academic / Other
Sex
All
Age
20 Years – 55 Years
Healthy volunteers
Not accepted

Summary

The study of the relationship between sleep pattern, attention performance, and heart rate variability among night workers.

Detailed description

Background: Previous study found that sleeping in the morning or evening pattern might be associated with performance among night workers. Both their sleep quality and circadian rhythm are critical for the performance at night. The study aims to identify the association between sleep pattern and performance among night workers. The effectiveness of interventions either supplement with melatonin for those who not meeting the DSM-5 criteria of Circadian Rhythm Sleep-Wake Disorders, CRSWD and prescription of melatonin agonist ramelteon for those who meet the DSM-5 criteria of CRSWD will be evaluated. Methods: The investigators will prescribe melatonin agonist ramelteon for 80 subjects those who agree to participate and meet the DSM-5 diagnostic criteria of this Circadian Rhythm Sleep Wake Disorders. They will receive the assessments including questionnaires and performance measurements before and after prescription with melatonin agonist 8 mg for 2 weeks to investigate the effectiveness of melatonin agonist. Anticipated outcome: The study will help the understanding the association of sleep pattern and performance among night workers. The effectiveness of either supplement with melatonin and prescription of melatonin agonist will be evaluated. The findings of our study might be implicated in the plans of intervention for better performance for night warriors.

Conditions

Interventions

TypeNameDescription
DRUGRamelteoncomparison of anxiety/depression, insomnia symptoms severity between before and after treatment with 8mg Ramelteon per day for two weeks among shift time workers.

Timeline

Start date
2024-03-04
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2026-02-03
Last updated
2026-02-03

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT07382843. Inclusion in this directory is not an endorsement.